This	O
HER2	O
immunohistochemical	O
assay	O
has	O
been	O
validated	O
according	O
to	O
the	O
recently	O
revised	O
.	O
recommendations	O
and	O
guidelines	O
from	O
the	O
NCCN	O
HER2	O
testing	O
in	O
Breast	O
Cancer	O
Task	O
Force	O
,	O
and	O
the	O
.	O
jointly	O
issued	O
recommendations	O
and	O
guidelines	O
from	O
ASCO	O
and	O
the	O
CAP	O
(	O
5	O
)	O
.	O
